Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Forbes 
No comment yet.
Sign up to comment
Scoop.it!
Dra. Almudena Valero Especialista en Glaucoma y Córnea HOSPITAL PUERTA DEL MAR
Las inyecciones intravítreas son una terapia efectiva para la degeneración macular asociada a la edad. Aunque el perfil farmacocinético de ranibizumab intravítreo (Lucentis®) no esta totalmente determinado en el hombre, en modelos animales si se han detectado niveles de la sustancia en humor acuoso. Con lo parece razonable valorar su citotoxicidad sobre el endotelio corneal.
Scoop.it!
Rueda de prensa de Gregory Winter y Richard Lerner. Reciben el premio príncipe de asturias de 2012 por sus importantes descubrimientos para el desarrollo de los anticuerpos monoclonales "humanizados" y su uso en el tratamiento de patologías.
Scoop.it!
for physicians or Medical Students
Clinical Context Although biologic agents have greatly improved outcomes for patients with autoimmune diseases, substantial concern remains about risk for serious infections associated with these drugs. A previous study by Grijalva and colleagues (JAMA. 2011;306:2331-2339) examined 1172 cases of serious infection among patients with rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. Pneumonia and skin or soft tissue infection accounted for most cases of infection. Compared with nonbiologic treatment regimens, anti–tumor necrosis factor (TNF) drugs were not associated with a significant increase in the risk for infection in any disease state studied. Nonetheless, the rate of serious infection among patients with RA treated with biologic agents is estimated to be 3 to 7 infections per 100 person-years. The current study by Curtis and colleagues examined factors that might predict a higher rate of serious infection associated with the use of anti-TNF drugs for RA.
Scoop.it!
Louis M. Weiner,Joseph C. Murray,Casey W. Shuptrine By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy. http://dx.doi.org/10.1016/j.cell.2012.02.034, How to Cite or Link Using DOI
|
Scoop.it!
Clinical Implications of Basic Research from The New England Journal of Medicine — Immunotherapy for HIV Infection.
Alfredo Corell's insight:
Immunotherapy for HIV Infection Robin A. Weiss, Ph.D. N Engl J Med 2014; 370:379-380January 23, 2014DOI: 10.1056/NEJMcibr1314577 Two recent studies show that a hybrid virus, the simian immunodeficiency virus bearing the envelope antigens of HIV-1, can be cleared from the blood of rhesus macaques by the infusion of monoclonal antibodies.
Scoop.it!
Ranibizumanb in the treatment of the Macular Degeneration. A complete 3D video showing the mechanism of the disease and the action of the Monoclonal Antibodie.
Scoop.it!
El Ministerio de Sanidad ha aprobado el uso y la financiación pública del ipilimumab, una novedosa inmunoterapia contra el melanoma metastásico. Según los ensayos del laboratorio que lo ha desarrollado, BMS, este fármaco prolonga la supervivencia de los afectados de una media de seis o nueve meses a hasta cinco años.
Scoop.it!
Prof. G.V. Scagliotti and Prof. Tony Mok
CONTENTS: -Introduction -LUX-Lung 3: Improved Quality of Life, as Expected -PSF v OS: why the disparity? -Reversible and Irreversible TKI -Crizotinib: Standard of Care for ALK-Positive Disease -Unusual Toxicity Profile of Crizotinib -Crizotinib of Benefit to ROS1-Positive Patients -A Durg for Every Mutation
Scoop.it!
Conclusions Anti–PD-1 antibody produced objective responses in approximately one in four to one in five patients with non–small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.)
Link to NEJM:
|
It’s hard to keep track of practice-changing drugs for chronic lymphocytic leukemia (CLL). Since last November, the FDA has approved three new agents and expanded indications for another to treat this indolent cancer of white blood cells. As someone who spent over ten years studying this form of leukemia, I’m thrilled by the science behind these targeted medicines, and by the potentially life-saving new options for people with this condition.